This week, the FDA has issued a warning to physicians and patients that the intravenous antibiotic Cubicin can cause life-threatening eosinophilic pneumonia, which is caused the accumulation of a type of white blood cells, called eosinophils, in the lungs. Symptoms include fever, cough, shortness of breath and difficult breathing. According to their data, The FDA has identified seven confirmed cases of eosinophilic pneumonia between 2004 and 2010 and an additional 36 possible cases. Of the seven confirmed cases, all were older than 60, and all were prescribed Cubicin for non-FDA approved conditions. Cubicin was approved in September 2003 for treatment of sercous skin infections and in 2006 for the treatment of bloodstream infections. In 2007 its label was modified to indicate an increased risk for pulmonary eosinophilia, the increased concentration of eosinophis in the blood. The FDA has requested that Cubist, the manufacturer of the product, revise its label to reflect the newly recognized danger.
News like this suggests approval by the FDA hardly has anything to do with the safety or efficacy of a drug. What is more, by the time a drug is recalled, many people have already been injured or killed. As drug companies continue to market new drugs and downplay serious health effects in their relentless pursuit of profit, the public will always be at risk. Each year United States and multi-national pharmaceutical companies bring new and different products to market–some of which have adequately been tested and some that have not. Many of these drugs are causing human pain and suffering, rather than relieving it. Here at the Brod Law Firm, we have experience representing victims of injury and wrongful death due to prescription, and non-prescription drugs, which have caused harm. Whether you or a loved one have sustained injury or death as the result of preventable side effects from a prescription drug or over-the-counter remedy, we are available to investigate your claim and represent you if your loss is the result of drug manufacturer wrongdoing.